Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Arix Bioscience plc
  6. News
  7. Summary
    ARIX   GB00BD045071

ARIX BIOSCIENCE PLC

(ARIX)
  Report
Delayed Quote. Delayed London Stock Exchange - 05/14 11:35:08 am
184 GBX   -0.27%
05/14Transaction in own shares
DJ
05/12Autolus to present additional data in AUTO1 in IBCL
DJ
05/10Transaction in own shares
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Total Voting Rights

05/04/2021 | 02:01am EDT
Arix Bioscience PLC (ARIX) 
Total Voting Rights 
04-May-2021 / 07:00 GMT/BST 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Arix Bioscience plc 
 
Total Voting Rights 
In conformity with 5.6.1R of the Disclosure Guidance and Transparency Rules, Arix Bioscience plc announces that its 
total issued share capital at the close of business on 30 April 2021 comprised 135,609,653 Ordinary Shares of 0.001 
pence each fully paid. This figure includes 2,311,853 Ordinary Shares which are held in Treasury, leaving a balance of 
133,297,800 Ordinary Shares with voting rights. 
The above figure of 133,297,800 may be used by shareholders for the calculations by which they will determine if they 
are required to notify their major interest in, or a change to their major interest in, Arix Bioscience plc under the 
Disclosure Guidance and Transparency Rules. 
 
[ENDS] 
 
For further information, please contact: 
 
Arix Bioscience plc 
Charlotte Parry, Head of Investor Relations 
+44 (0)20 7290 1072 
charlotte@arixbioscience.com 
 
 
 
=---------------------------------------------------------------------------------------------------------------------- 
ISIN:           GB00BD045071 
Category Code:  TVR 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 2.5. Total number of voting rights and capital 
Sequence No.:   102726 
EQS News ID:    1191460 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------
 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1191460&application_name=news 
 

(END) Dow Jones Newswires

May 04, 2021 02:00 ET (06:00 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
ARIX BIOSCIENCE PLC -0.27% 184 Delayed Quote.-15.98%
DJ INDUSTRIAL 1.06% 34382.13 Delayed Quote.11.16%
All news about ARIX BIOSCIENCE PLC
05/14Transaction in own shares
DJ
05/12Autolus to present additional data in AUTO1 in IBCL
DJ
05/10Transaction in own shares
DJ
05/06Transaction in own shares
DJ
05/04Transaction in own shares
DJ
05/04Total Voting Rights
DJ
04/30Transaction in own shares
DJ
04/30ARIX BIOSCIENCEá : Executive Chairman Exits; COO Appointed as Interim CEO
MT
04/30Outcome of Strategic Implementation Review and Directorate Change
DJ
04/28ARIX BIOSCIENCEá : Pfizer Snaps Up Arix Bioscience Portfolio Company
MT
More news
Financials
Sales 2021 0,50 M 0,71 M 0,71 M
Net income 2021 37,7 M 53,2 M 53,2 M
Net cash 2021 175 M 247 M 247 M
P/E ratio 2021 6,37x
Yield 2021 -
Capitalization 235 M 331 M 331 M
EV / Sales 2021 119x
EV / Sales 2022 128x
Nbr of Employees 12
Free-Float 73,5%
Chart ARIX BIOSCIENCE PLC
Duration : Period :
Arix Bioscience plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARIX BIOSCIENCE PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 221,50 GBX
Last Close Price 184,00 GBX
Spread / Highest target 39,1%
Spread / Average Target 20,4%
Spread / Lowest Target 1,63%
EPS Revisions
Managers and Directors
NameTitle
Robert Lyne CEO, COO, Secretary, Director & General Counsel
Christian Schetter Managing Director
Marcus Karia Group Finance Director
Peregrine D. E. M. Moncreiffe Non-Executive Chairman
Graeme Smith Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
ARIX BIOSCIENCE PLC-15.98%331
INVESTOR AB (PUBL)22.11%66 983
CK HUTCHISON HOLDINGS LIMITED15.16%30 932
AB INDUSTRIVÄRDEN (PUBL)19.26%16 665
HAL TRUST30.60%15 822
KINNEVIK AB-1.10%14 008